Issue Per-patient cost above $100,000 could confine the therapy to well-resourced health systems

Summary

The strategic outlook names access as the central risk: early treatments exceeding $100,000 per patient could restrict personalized vaccines to well-resourced health systems and widen existing global gaps in cancer outcomes, which it frames as the question of whether precision medicine becomes a privilege rather than a standard of care.